The Interaction Between FAK, MYCN, p53 and Mdm2 in Neuroblastoma

ISSN: 1875-5992 (Online)
ISSN: 1871-5206 (Print)

Volume 17, 14 Issues, 2017

Download PDF Flyer

Anti-Cancer Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Cancer Agents

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 27th of 59 in Chemistry, Medicinal

Submit Abstracts Online Submit Manuscripts Online

Michelle Prudhomme
Institut de Chimie de Clermont-Ferrand
Université Clermont Auvergne

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.722
5 - Year: 2.849

The Interaction Between FAK, MYCN, p53 and Mdm2 in Neuroblastoma

Anti-Cancer Agents in Medicinal Chemistry, 14(1): 46-51.

Author(s): Alicia M. Waters and Elizabeth A Beierle.

Affiliation: University of Alabama at Birmingham, 1600 7th Ave. South, Lowder Room 300, Birmingham, AL 35233, USA.


Neuroblastoma tumorigenesis and malignant transformation is driven by overexpression and dominance of cell survival pathways and a lack of normal cellular senescence or apoptosis. Therefore, manipulation of cell survival pathways may decrease the malignant potential of these tumors and provide avenues for the development of novel therapeutics. This review focuses on the individual protein tyrosine kinase, focal adhesion kinase (FAK) and its interaction with the transcription factors, MYCN, p53, and Mdm2, and how their interactions modulate the growth and malignancy of neuroblastomas.


FAK, Mdm2, MYCN, neuroblastoma, p53.

Download Free Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 14
Issue Number: 1
First Page: 46
Last Page: 51
Page Count: 6
DOI: 10.2174/18715206113136660331

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science